Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686135 | 0.88 | TSHR (0.59) | KMT2AKDM4EALDH1A1MAPK10MEN1 | |
| SCHEMBL9686940 | 0.87 | GAA (0.45) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL6462475 | 0.85 | ALOX5 (0.51) | PTGS2KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL7046945 | 0.84 | PTGS2 (0.57) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL499116 | 0.82 | GAA (0.61) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL4965033 | 0.82 | PTGS2 (0.55) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL2307800 | 0.82 | PTGS2 (0.55) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL2930056 | 0.81 | HTR2A (0.59) | PTGS2HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL10744953 | 0.81 | ALDH1A1 (0.56) | KMT2AKDM4EALDH1A1MAPK10MEN1 | |
| SCHEMBL31186754 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HTTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. | 2025-05-22 | — | — | US | claimed |
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | JOURNEY COLAB CORP. | 2024-07-25 | — | — | US | claimed |
| WO-2023164178-A2 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2022251690-A1 | MESCALINE FOR THE TREATMENT OF SUBSTANCE USE DISORDERS | JOURNEY COLAB CORP. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. | 2025-05-22 | — | — | US | disclosed |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. | 2025-05-22 | — | — | US | disclosed |
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | JOURNEY COLAB CORP. | 2024-07-25 | — | — | US | disclosed |
| CN-117723691-A | Detection method of 1- [3- (dimethylamino) propyl ] -3-ethylurea | 珠海优泽生物科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| WO-2023164178-A3 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023164178-A2 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164178-A2 | METHODS FOR PREPARING MESCALINE | JOURNEY COLAB CORP. (US) | 2023-08-31 | — | — | WO | disclosed |
| CN-116496281-A | Benzonitrogen Zhuo Luo indoline compound and synthetic method and application thereof | 重庆文理学院 | 2023-07-28 | — | — | CN | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0514667-B1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 1995-08-09 | — | — | EP | disclosed |
| EP-0620003-A1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5244898-A | Vasopressin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0514667-A1 | Benzazepin derivatives as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-25 | — | — | EP | disclosed |
| EP-0306440-A2 | 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | disclosed |
| US-4668814-A | ANTIULCER AGENTS, ANTIASHMATICS, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245632-A1 | METHODS OF TREATING SUBSTANCE USE DISORDERS USING MESCALINE | SLC6A12, SLC6A3, TPMT | PTGS2 3134/4885HTR2A 93/4885HTR2C 24/4885 |
| US-20250162980-A1 | METHODS FOR PREPARING MESCALINE | IL4I1, ME3, LIG3 | PTGS2 3397/4885HTR2A 3249/4885HTR2C 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.